RWBEX
Price
$65.17
Change
-$4.61 (-6.61%)
Updated
Dec 17 closing price
RWIBX
Price
$64.43
Change
-$4.56 (-6.61%)
Updated
Dec 17 closing price
Ad is loading...

RWBEX vs RWIBX

Header iconRWBEX vs RWIBX Comparison
Open Charts RWBEX vs RWIBXBanner chart's image
American Funds Capital World Gr&Inc R2E
Price$65.17
Change-$4.61 (-6.61%)
VolumeN/A
CapitalizationN/A
American Funds Capital World Gr&Inc R2
Price$64.43
Change-$4.56 (-6.61%)
VolumeN/A
CapitalizationN/A
RWBEX vs RWIBX Comparison Chart
Loading...
View a ticker or compare two or three
VS
RWBEX vs. RWIBX commentary
Dec 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RWBEX is a Buy and RWIBX is a Buy.

FUNDAMENTALS
Fundamentals
RWBEX (130B) and RWIBX (130B) have equal amount of cash in the bank . RWBEX pays higher dividends than RWIBX: RWBEX (1.28) vs RWIBX (1.05). RWBEX was incepted earlier than RWIBX: RWBEX (10 years) vs RWIBX (23 years). RWBEX (27.00) and RWIBX (27.00) have comparable annual turnover. RWBEX (250) and RWIBX (250) have matching initial minimum investment requirements. RWBEX (11.66) and RWIBX (11.34) have marching annual gain over last year. RWBEX (30.86) and RWIBX (29.64) have equivalent 5 years return.
RWBEXRWIBXRWBEX / RWIBX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence10 years23 years-
Gain YTD10.0919.781103%
Front LoadN/AN/A-
Min. Initial Investment250250100%
Min. Initial Investment IRAN/AN/A-
Net Assets130B130B100%
Annual Yield % from dividends1.281.05122%
Returns for 1 year11.6611.34103%
Returns for 3 years9.088.41108%
Returns for 5 years30.8629.64104%
Returns for 10 years45.5544.22103%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LITM0.180.03
+17.46%
Snow Lake Resources Ltd
NUVB2.810.12
+4.46%
Nuvation Bio
ENTG109.362.65
+2.48%
Entegris
ARQ7.01-0.04
-0.57%
Arq
PTCT47.02-1.59
-3.27%
PTC Therapeutics